$7.83 Billion is the total value of Flagship Pioneering Inc.'s 33 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | $4,836,127,000 | +79.4% | 20,581,016 | 0.0% | 61.77% | +43.1% | |
| RUBY | Rubius Therapeutics Inc | $939,945,000 | -7.9% | 38,506,526 | 0.0% | 12.00% | -26.5% | |
| SANA | Sana Biotechnology Inc | $673,139,000 | -41.3% | 34,239,018 | 0.0% | 8.60% | -53.2% | |
| MCRB | Sell | Seres Therapeutics Inc | $342,935,000 | +13.5% | 14,378,802 | -2.0% | 4.38% | -9.5% |
| EVLO | Evelo Biosciences Inc | $316,433,000 | +28.4% | 23,030,069 | 0.0% | 4.04% | +2.4% | |
| DNLI | Denali Therapeutics Inc | $214,162,000 | +37.4% | 2,730,263 | 0.0% | 2.74% | +9.5% | |
| KLDO | Kaleido Biosciences Inc | $145,643,000 | -8.1% | 19,575,710 | 0.0% | 1.86% | -26.7% | |
| FHTX | Foghorn Therapeutics Inc | $135,233,000 | -19.0% | 12,674,120 | 0.0% | 1.73% | -35.4% | |
| SGTX | Sigilon Therapeutics Inc | $111,274,000 | -52.0% | 10,370,369 | 0.0% | 1.42% | -61.7% | |
| AXLA | Axcella Health Inc | $50,319,000 | -15.8% | 12,548,414 | 0.0% | 0.64% | -32.8% | |
| CDAK | Codiak Biosciences Inc | $48,314,000 | +22.9% | 2,607,303 | 0.0% | 0.62% | -2.1% | |
| SYRS | Syros Pharmaceuticals Inc | $16,015,000 | -27.1% | 2,938,494 | 0.0% | 0.20% | -41.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.